Com­pound­ing drugs dur­ing the pan­dem­ic: FDA of­fers pol­i­cy clar­i­fi­ca­tions

In re­sponse to “many emails from stake­hold­ers,” the FDA late Mon­day clar­i­fied a few poli­cies re­lat­ed to drug com­pound­ing, in­clud­ing one on the lim­it on the in­ter­state dis­tri­b­u­tion of com­pound­ed drug prod­ucts for phar­ma­cy com­pounders.

Over­all, FDA said its poli­cies are meant to pro­tect pa­tients from un­safe, in­ef­fec­tive and poor-qual­i­ty com­pound­ed drugs while pre­serv­ing ac­cess for pa­tients.

In one of the up­dates, FDA clar­i­fies that a draft guid­ance has not tak­en ef­fect and will be re­vised. The guid­ance notes that FDA will not take ac­tion against cer­tain en­ti­ties as long as drugs are dis­trib­uted on­ly to health­care fa­cil­i­ties that are owned and con­trolled by the same en­ti­ty that owns and con­trols the hos­pi­tal phar­ma­cy and that are lo­cat­ed with­in a one-mile ra­dius of the com­pound­ing phar­ma­cy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER